UROTHELIAL CANCER TREATMENT MARKET ANALYSIS

Regional Analysis

Global Urothelial Cancer Treatment Market – Regional Insights

North America accounted for the largest market share in 2018. This is attributed to rising incidences of bladder cancers in the region. For instance, in January 2020, the American Cancer Society estimated that, approximately 81,400 people are expected to get diagnosed with bladder cancer in the U.S in year 2020. 

Moreover, key players are focusing on enhancing their product portfolio through product launches and new product approvals for urothelial cancer treatment, which is expected to boost urothelial cancer treatment market growth over the forecast period in the region. For instance, in February 2017, Bristol-Myers Squibb Company received the U.S Food and Drug Administration approval for Opdivo, an injection developed for the patients with metastatic locally or advanced urothelial carcinoma.

Europe is expected to be the second-largest market for global urothelial cancer treatment market and it is projected to witness significant growth over the forecast period, owing to increasing cases of bladder cancer in the region. For instance, according to the Cancer Research UK, approximately 10,187 new cases of bladder cancer were registered from 2014 to 2016 in the UK.